Sonnet BioTherapeutics Holdings shares are trading higher after the company announced FDA acceptance of its IND for the SB221 clinical trial of SON-1010 combined with atezolizumab.
Portfolio Pulse from Benzinga Newsdesk
Sonnet BioTherapeutics Holdings announced that the FDA has accepted its Investigational New Drug (IND) application for the SB221 clinical trial of SON-1010 combined with atezolizumab. This news has led to an increase in the company's share price.
August 16, 2023 | 3:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sonnet BioTherapeutics' stock is trading higher following the FDA's acceptance of its IND for the SB221 clinical trial. This could potentially lead to positive outcomes for the company's drug development.
The FDA's acceptance of Sonnet BioTherapeutics' IND is a significant regulatory milestone that allows the company to proceed with its clinical trial. This positive news has led to an increase in the company's share price, indicating investor confidence in the company's drug development prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100